Syk and Zap-70 are related protein-tyrosine kinases implicated in antigen and Fc receptor signaling. While Zap-70 is restricted to T-cells and natural killer cells, Syk accumulates in B-cells, mast cells, platelets, and immature T-cells. In addition, we found that an isoform of Syk (SykB), which carries a 23-amino acid deletion in the "linker" region, is prominently expressed in bone marrow. To better understand the relative impact of Syk, SykB, and Zap-70 on signal transduction, we compared their intrinsic enzymatic properties in transiently transfected COS-1 cells and in hemopoietic cells. Using modified versions of these enzymes bearing a common Myc epitope at the amino terminus, we determined that the ability of Syk and SykB to undergo autophosphorylation and to phosphorylate erythrocyte band 3 in immune complex kinase reactions was at least 100-fold greater than that of Zap-70. Similarly, Syk and SykB, but not Zap-70, caused prominent tyrosine phosphorylation of p120 c-cbl in COS-1 cells. A similar pattern of activity was also noted for endogenous Syk and Zap-70 from hemopoietic cells. To understand the structural basis for these characteristics, we also created and analyzed a series of chimeras between Syk and Zap-70. These studies indicated that the catalytic domain of Syk and Zap-70, but not their SH2 domains, linker region or carboxyl-terminal tail, was responsible for their respective activity. Taken together, these data demonstrated that the intrinsic enzymatic activity of Syk and SykB is superior to that of Zap-70 and that such a distinction relates to structural variations in the catalytic domain.
The Syk family of nonreceptor protein-tyrosine kinases (PTKs) 1 comprises two known members termed Zap-70 and Syk (reviewed in Ref. 1) . Zap-70 is solely expressed in T-cells and natural killer (NK) cells, whereas Syk accumulates in most hemopoietic cell types, including B-cells, mast cells, platelets, and immature T-cells. The structure of Syk family kinases is highly conserved, including from the amino terminus to the carboxyl terminus: 1) two Src homology 2 (SH2) domains, implicated in interactions with tyrosine-phosphorylated proteins; 2) a "linker" region of 80 -110 amino acids, which is postulated to bind cellular effectors (2); 3) a catalytic domain, including sites of ATP binding and autophosphorylation; and 4) a short carboxyl-terminal extension of yet undetermined function (Fig. 1A) .
Over the past few years, evidence has accumulated that Zap-70 and Syk participate in signal transduction through antigen and Fc receptors in hemopoietic cells (reviewed in Ref. 1) . Engagement of these receptors by the appropriate ligand triggers tyrosine phosphorylation of receptor-associated subunits, within a tyrosine-based motif termed ITAM (for immunoreceptor tyrosine-based activation motif). This event is seemingly mediated by members of the Src family of PTKs. Subsequently, Zap-70 and Syk bind doubly phosphorylated ITAMs via their tandem SH2 domains and undergo phosphorylation on multiple tyrosine residues. By reconstituting these interactions in COS cells, it has been concluded that tyrosine phosphorylation of Zap-70 and Syk is mediated both by Src family kinases and, to a lesser extent, by autophosphorylation (3) (4) (5) (6) . Binding of Zap-70 and Syk to ITAMs also augments their catalytic activity, presumably as a result of tyrosine phosphorylation and conformational modification (7) (8) (9) (10) . Tyrosine phosphorylation of Syk family kinases may also create docking sites allowing the recruitment of other SH2 domain-containing signaling molecules (2, 10) .
Genetic evidence supports the notion that Zap-70 and Syk provide essential functions in signaling through antigen and Fc receptors. Takata et al. (11) showed that Syk-deficient DT-40 B-cells exhibited markedly decreased B-cell antigen receptor (BCR)-induced protein tyrosine phosphorylation and calcium flux. Similarly, expression of kinase-defective versions of Syk blocked signaling through Fc receptor for IgE (Fc⑀RI) in RBL-2H3 basophilic leukemia cells (12) , whereas introduction of Zap-70 polypeptides devoid of catalytic domain inhibited T-cell antigen receptor-mediated signals in Jurkat T-cells (13) . A crucial role for Zap-70 and Syk in hemopoietic cell development was also implied by analyses of human or mouse mutants lacking these enzymes. Humans and mice lacking Zap-70 were shown to have markedly abnormal T-cell maturation (14 -17) . Conversely, Syk-deficient mice demonstrated altered B-cell development, reduced hemostasis, and embryonic lethality (18, 19) . Proper maturation of some subsets of ␥␦ T-cells was also defective in these animals.
Even though the exact mechanism by which Zap-70 and Syk mediate their biological functions is not understood, the creation of chimeric molecules linking Zap-70 or Syk to the transmembrane and extracellular domains of unrelated molecules indicated that they directly couple to effectors of cellular activation (20, 21) . Antibody-mediated aggregation of a CD16-CD7-Syk chimera was sufficient to cause an elevation of cytoplasmic calcium and induce cytolytic functions in T-cell lines (20) . Similarly, it provoked degranulation of RBL-2H3 cells (21) . Intriguingly though, stimulation of the equivalent Zap-70 chimera induced a rise in intracellular calcium in T-cells, but failed to induce cytolysis (20) . Co-aggregation of this chimera with a Fyn or Lck chimera was necessary to trigger cytotoxicity. These data led to the proposal that the function and/or regulation of Zap-70 and Syk may not be identical.
To evaluate whether these findings were caused by differences in the intrinsic PTK activity of Zap-70 and Syk, we undertook a series of experiments contrasting their biochemical properties. Using versions of mouse Zap-70 and Syk carrying a common Myc epitope at their amino terminus, we found that Syk is significantly more active than Zap-70 both in in vivo and in vitro assays. Such a difference was observed not only for molecules expressed in COS-1 cells, but also for endogenous Zap-70 and Syk polypeptides contained in hemopoietic cells. Through construction of chimeras between Zap-70 and Syk, it was also established that these biochemical differences relate to sequence variations in the catalytic domain of these polypeptides. Collectively, these data implied that the ability of Syk to participate in hemopoietic cell signaling is greater than that of Zap-70 at least in part as a consequence of its superior intrinsic PTK activity.
MATERIALS AND METHODS
Cells-COS-1 cells were propagated in ␣ minimal essential medium supplemented with 10% fetal calf serum and antibiotics. WEHI-231 mouse B-lymphoma cells were obtained from the American Type Culture Collection, Rockville, MD. A20/2J is a mouse B-cell lymphoma cell line (22) , and BI-141 is an antigen-specific mouse T-cell hybridoma (23) . All hemopoietic cells were grown in RPMI 1640 medium containing 10% fetal calf serum and antibiotics. Splenocytes, thymocytes, and bone marrow cells were isolated from 4 -6-week-old Balb/c mice. For preparation of splenocytes and bone marrow cells, erythrocytes were depleted by incubation in ACK buffer (24) .
Antibodies-Anti-Syk antibodies were produced in rabbits using a TrpE fusion protein encompassing amino acids 258 -356 of mouse Syk (25, 26) . Rabbit antisera directed against amino acids 253-329 of Zap-70, or against c-Cbl, were described elsewhere (27, 28) . Monoclonal antibody (mAb) 9E10 is a mouse antibody directed against human c-Myc (29) . mAb 4G10 is a mouse anti-phosphotyrosine mAb purchased from Upstate Biotechnology Inc., Lake Placid, New York. Affinitypurified rabbit anti-phosphotyrosine antibodies were reported previously (30) .
cDNAs-Mouse syk cDNAs were cloned from a day 16 fetal thymus cDNA library (kindly provided by Dr. Louis Matis, Alexion Pharmaceuticals, New Haven, CT), using a partial cDNA corresponding to the linker region of Syk as a probe. Representative full-length cDNAs were sequenced to ensure that they contained no mutation (data not shown). cDNA clones 4 and 5, which correspond to syk and sykB, respectively, were utilized in our studies. Mouse zap-70 cDNA (31) was kindly provided by Dr. Andrey Shaw, Washington University, St. Louis, MO. Mouse c-cbl cDNA was described previously (28) .
Ribonuclease Protection Assays-Ribonuclease protection assays were performed according to a previously published protocol (32) . To generate the riboprobe, a 239-nucleotide BstEII-AccI fragment corresponding to amino acids 279 -356 of mouse Syk was cloned in pGEM3. After linearization with HindIII, antisense riboprobes of 304 nucleotides were synthesized with T7 RNA polymerase (Pharmacia Biotech. Inc.) ( Fig. 2A, bottom diagram) . Full protection by syk transcripts was expected to yield a fragment of 239 nucleotides, whereas protection by sykB RNAs was predicted to generate a 175-nucleotide fragment. Endlabeled MspI-digested pBR322 fragments were used as size markers. Relative levels of syk RNA expression were established using a phosphorimager (BAS 2000; Fuji, Stamford, CT).
Construction of myc-tagged cDNAs-myc-tagged versions of syk, sykB, and zap-70 were generated by creating an EcoRI site around the initiating ATG of these cDNAs, through polymerase chain reaction. The resulting products were sequenced to ensure that no unwanted mutations had been introduced (data not shown). After digestion with EcoRI and XhoI, the fragments were cloned in-frame into the same sites of pBluescript Myc tag (from Dr. A. Shaw). As a result, the sequence MASMEQKLISEEDLNNGNS was added to the amino terminus of Syk, SykB, and Zap-70, thereby creating Myc-Syk, Myc-SykB, and Myc-Zap-70. The underlined amino acids are derived from human Myc and are recognized by mAb 9E10 (Ref. 29) .
Generation of Syk-Zap and Zap-Syk Chimeras-Chimeras between Syk and Zap-70 were produced by polymerase chain reaction (Fig. 7) Transfections-cDNAs were individually inserted in the multiple cloning site of pXM139, a vector that bears the SV40 origin of replication. COS-1 cells were transfected by the DEAE-dextran method, using a fixed total amount of DNA (28) . After 12 h, cells were incubated with chloroquine (60 g/ml) for 5 h. Following an additional growth period of 48 h, cells were processed for immunoprecipitation and immunoblotting.
Immunoprecipitations and Immunoblots-After washing in phosphate-buffered saline, cells were lysed in TNE buffer (50 mM Tris, pH 8.0, 1% Nonidet P-40, 2 mM EDTA) supplemented with 10 g/ml each of the protease inhibitors leupeptin, aprotinin, N-tosyl-L-phenylalanine chloromethyl ketone, N-p-tosyl-L-lysine chloromethyl ketone, and phenylmethylsulfonyl fluoride, as well as the phosphatase inhibitors sodium fluoride (50 mM) and sodium orthovanadate (1 mM). Polypeptides were recovered by immunoprecipitation using the indicated antibodies. Immune complexes were collected with Staphylococcus aureus protein A (Pansorbin, Calbiochem), coupled, if indicated, to rabbit anti-mouse immunoglobulin (Ig) G. Immunoprecipitates were washed three times with TNE buffer containing 1 mM sodium orthovanadate. Proteins were then eluted in sample buffer, boiled, electrophoresed in 8% SDS-polyacrylamide gel electrophoresis gels, and transferred onto Immobilon membranes (Millipore, Mississauga, Ontario, Canada) for immunoblotting. Immunoblots were performed according to a previously described protocol (33) . After incubation with 125 I-protein A (Amersham Canada, Oakville, Ontario, Canada) or 125 I-goat anti-mouse IgG (ICN Pharmaceuticals Canada Ltd., Montréal, Québec, Canada), immunoreactive products were detected by autoradiography, and quantitated with a phosphorimager.
In depletion experiments, phosphotyrosine-containing proteins were removed by immunoprecipitation with anti-phosphotyrosine mAb 4G10. Then, Myc-tagged polypeptides were isolated by immunoprecipitation with mAb 9E10 and tested as described in the text.
Immune Complex Kinase Assays-These assays were done under linear conditions according to a previously described protocol (34) , with the exception that the kinase reactions were performed in 25 l of a buffer containing 20 mM Tris, pH 7.5, 10 mM MnCl 2 , 10 mM MgCl 2 , 1 M nonradioactive ATP, and 12.5 Ci of [␥-
32 P]ATP (3000 Ci/mmol; DuPont NEN), as well as 1 g of the cytoplasmic domain of erythrocyte band 3 (cdb3). Reactions were conducted at room temperature for the indicated periods of time. Data were quantitated with a phosphorimager.
RESULTS

Expression of an Additional Syk Isoform in Normal Mouse
Bone Marrow Cells-Previous studies have identified an alternative syk transcript in human Jurkat leukemia T-cells (35) and RBL-2H3 rat basophilic leukemia cells (36) . This variant, termed sykB, carried a deletion of a 69-nucleotide exon (36) and was expected to encode a Syk protein lacking 23 amino acids in the linker region (amino acids 277-299 for the mouse Syk protein; Ref. 26) . While attempting to clone syk cDNAs from normal mouse fetal thymus, we found one of 10 independent cDNA clones having a similar 69-nucleotide deletion ( Fig. 1B ; data not shown). To ascertain whether transcripts corresponding to this cDNA accumulated in mouse cells, ribonuclease protection assays were performed using total RNAs from a series of cell lines and tissues ( Fig. 2A) . While regular syk transcripts (hereafter identified as syk) were expected to protect a 239-nucleotide fragment of the riboprobe, sykB RNAs were predicted to cover a smaller 175-nucleotide fragment.
syk RNAs were easily detected in fetal and adult thymus ( Fig To ascertain whether the SykB protein was expressed in normal cells, Syk polypeptides were immunoprecipitated from spleen, thymus, or bone marrow and were detected by immunoblotting with a polyclonal rabbit anti-Syk serum (Fig. 2B ). This assay revealed that spleen (lane 1) and thymus (lane 2) primarily contained a 72-kDa immunoreactive product (p72 syk ), which comigrated with the Syk protein immunoprecipitated from COS-1 cells transfected with a mouse syk cDNA (lane 5). The SykB protein could not be clearly identified in these cells. In contrast, normal bone marrow cells (lane 3) possessed equal amounts of two distinct proteins, resolving at 70 and 72 kDa in these gels. These polypeptides comigrated with the Syk proteins recovered from COS-1 cells transfected with sykB and syk cDNAs, respectively (lanes 4 and 5). Whereas spleen and bone marrow expressed approximately equivalent quantities of total syk transcripts ( Fig. 2A) , it is noteworthy that bone marrow cells contained significantly lower amounts of Syk proteins (Fig. 2B) . Possibly, the Syk proteins were less stable in bone marrow cells. Alternatively, the translational efficiency of syk RNAs was perhaps diminished in these cells. Fig. 3B, bottom panel) . To begin characterizing the properties of these polypeptides, their extent of tyrosine phosphorylation was directly examined. Lysates were immunoprecipitated with anti-Myc mAb 9E10 and subjected to immunoblotting with anti-phosphotyrosine antibodies (Fig. 3A,  top panel) . Myc-Syk (lane 2) and Myc-SykB (lane 3) were clearly tyrosine-phosphorylated in COS-1 cells. In contrast, however, Myc-Zap-70 (lane 4) did not contain any appreciable amount of phosphotyrosine. These differences did not relate to variations in the abundance of the three polypeptides, as judged by an immunoblot of parallel immunoprecipitates with anti-Myc mAb 9E10 (Fig. 3A, bottom panel) . Similar results were obtained with nontagged versions of these enzymes (data not shown).
Syk and SykB, but Not Zap-70, Enhance Protein-tyrosine Phosphorylation in COS-1 Cells-In
Recently, the proto-oncogene product p120 c-cbl was shown to undergo prominent tyrosine phosphorylation during antigen receptor-mediated activation of T-cells and B-cells (37, 38) . This phosphorylation is thought to be mediated both by Srcrelated enzymes and Syk-related enzymes. Hence, to further compare the activity of Syk, SykB, and Zap-70, we examined their capacity to phosphorylate c-Cbl in COS-1 cells. Cells were transfected with cDNAs coding for the various Syk-related enzymes as described above, in the absence or presence of a mouse c-cbl cDNA. The extent of tyrosine phosphorylation of p120 c-cbl was determined by immunoblotting anti-Cbl immunoprecipitates with anti-phosphotyrosine antibodies (Fig. 3B, top  panel) . We found that expression of Myc-Syk (lane 6) and Myc-SykB (lane 7), but not of Myc-Zap-70 (lane 8), provoked tyrosine phosphorylation of the 120-kDa c-Cbl protein.
To ensure that the greater ability of Myc-Syk to phosphorylate c-Cbl was not the result of functional modifications provoked by addition of the Myc epitope, we also determined the effects of wild-type Syk and Zap-70 on c-Cbl tyrosine phosphorylation (Fig. 3C ). This assay revealed that, like Myc-Syk (lane (Fig. 4, top panel) . The relative abundance of the Myc-tagged proteins was also monitored by anti-Myc immunoblotting of parallel immunoprecipitates subjected to kinase reactions in the absence of radioactive ATP (bottom panel). This experiment demonstrated that Myc-Syk (lanes 6 -12) and Myc-SykB (lanes 13-18) underwent rapid phosphorylation in vitro. Moreover, they caused marked phosphorylation of erythrocyte band 3. In comparison, Myc-Zap-70 (lanes 1-6) was weakly phosphorylated and induced only minimal phosphorylation of the exogenous substrate. Quantitation of these data suggested that the kinase activity of Myc-Syk and Myc-SykB was at least 100-fold greater than that of Myc-Zap-70 in vitro. Similar results were obtained when lower amounts of Myc-tagged proteins were used or when the kinase reactions were conducted for shorter periods of time, under assay conditions that we had demonstrated to be linear (data not shown). Moreover, analogous findings were made over a wide range of reaction conditions, which included variations in buffer, pH, co-factor, and temperature (data not shown).
To ensure that the greater activity of Myc-Syk and MycSykB in these assays was not due to their prior tyrosine phosphorylation in COS-1 cells, tyrosine-phosphorylated molecules were depleted from cell lysates, and immune complex kinase reactions were performed on the remaining Myc-tagged molecules (Fig. 5) . Even though all tyrosine-phosphorylated MycSyk (Fig. 5A, top panel, lane 4) and Myc-SykB (lane 5) could be removed in this manner, these two enzymes (Fig. 5B, lanes 4 and 5, respectively) remained more efficient than Myc-Zap-70 (lane 6) at autophosphorylation and phosphorylation of band 3.
Syk and Zap-70 Also Exhibit Distinct Enzymatic Activities in Hemopoietic Cells-To verify that these differences also existed for endogenous Syk and Zap-70 molecules expressed in hemopoietic cells, similar experiments were conducted using hemopoietic cell lines. Preliminary studies had shown that the mouse B-cell lines WEHI-231 and A20/2J expressed Syk, but not Zap-70, while the mouse T-cell line BI-141 contained Zap-70, but not Syk (data not shown; Fig. 2A ). Unfortunately, we were not able to identify any mouse cell line that exclusively contained SykB. Following cell lysis, Syk and Zap-70 were immunoprecipitated using rabbit anti-Syk and anti-Zap-70 sera, respectively. As controls, Syk, Zap-70, and their Myctagged versions were also immunoprecipitated from transiently transfected COS-1 cells using the same antisera. Immune complex kinase reactions (Fig. 6 , top panel) were performed as described earlier, and the abundance of Syk and Zap Whereas the sequence of the SH2 regions and the kinase domain of these enzymes is highly conserved, that of their linker region and carboxyl-terminal tail is more divergent. To understand the structural basis for the biochemical differences noted above, chimeras between Syk and Zap-70 were created by polymerase chain reaction. In the first set of chimeras, the kinase domain and carboxyl-terminal tail of Syk were exchanged for those of Zap-70 and vice versa (Fig. 7) . In all cases, the chimeric proteins also possessed the Myc epitope at their amino terminus. The resulting polypeptides were termed Myc-Syk/Zap and Myc-Zap/Syk.
Like Myc-Syk (Fig. 8A, lane 1) and Myc-SykB (lane 2), the Myc-Zap/Syk chimera (lane 5) was prominently tyrosine-phosphorylated in COS-1 cells. On the contrary, Myc-Syk/Zap (lane 4) contained no appreciable amount of phosphotyrosine. Similarly, Myc-Zap/Syk (Fig. 8B, lane 6) provoked an increase in tyrosine phosphorylation of c-Cbl, while Myc-Syk/Zap (lane 5) did not. Finally, in immune complex kinase assays (Fig. 8C) , the activity of Myc-Zap/Syk (lane 5) was found to be comparable with that of Myc-Syk (lane 1) and Myc-SykB (lane 2). In contrast, Myc-Syk/Zap (lane 4) had a significantly lower activity, which was even lower than that of Myc-Zap-70 (lane 3).
To identify which element(s) in the carboxyl-terminal half of Syk was (were) required for its elevated kinase activity, a second series of chimeras was generated. In these chimeric proteins, the carboxyl-terminal tails of Syk and Zap-70 were exchanged, thereby creating Myc-Syk/Zap-tail and Myc-Zap/ Syk-tail (Fig. 7) . Immune complex kinase reactions revealed that transfer of the carboxyl terminus of Syk onto Zap-70 was insufficient to elevate the catalytic activity of Zap-70 (Fig. 9A,  top panel, lane 5) . Intriguingly, replacement of the tail of Syk by that of Zap-70 reduced its activity in vitro by ϳ2-3-fold (lanes 4 and 6) . However, Myc-Syk/Zap-tail (Fig. 9B, top panel,  lane 4) was at least as efficient as Myc-Syk (lane 2) at inducing tyrosine phosphorylation of p120 c-cbl . While the basis for this discrepancy is not known, it is possible that Myc-Syk/Zap-tail was more susceptible than Myc-Syk to denaturation during cell lysis, thereby explaining its lower activity in in vitro assays. Alternatively, replacement of the carboxyl-terminal tail of Syk by that of Zap-70 may modify the substrate specificity of Syk, rendering it more efficient at phosphorylating c-Cbl, while it was less apt at phosphorylating itself or band 3. In any case, these experiments clearly established that the catalytic domain, and not the carboxyl-terminal tail of Syk, was responsible for its superior activity in COS-1 cells.
DISCUSSION
In this manuscript, we have compared the enzymatic activity of Syk, SykB, and Zap-70. To facilitate our analyses, a Myc epitope was added to the amino terminus of all three molecules, allowing their recognition by the same antibody (mAb 9E10). In transiently transfected COS-1 cells, Myc-Syk and Myc-SykB provoked tyrosine phosphorylation of cellular proteins, including Myc-Syk and Myc-SykB themselves. In contrast, MycZap-70 had no effect. In a similar way, Myc-Syk and Myc-SykB, but not Myc-Zap-70, promoted tyrosine phosphorylation of p120 c-cbl , a known tyrosine phosphorylation substrate expressed in hemopoietic cells (37, 38) . Finally, we found that Myc-Syk and Myc-SykB had a ϳ100-fold greater ability to autophosphorylate and phosphorylate the exogenous substrate erythrocyte band 3 in vitro, when compared with Myc-Zap-70. Identical results were obtained when a human zap-70 cDNA was transiently expressed in COS-1 cells. 2 To verify that these differences were not restricted to COS-1 cells, the enzymatic activity of Syk and Zap-70 was also assayed using molecules immunoprecipitated from hemopoietic cells 
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2J) had comparable PTK activity in vitro. Furthermore, the activity of Zap-70 from COS-1 cells was similar to that of Zap-70 molecules isolated from a T-cell line (BI-141). Hence, the kinase activity associated with Syk molecules obtained from different sources was greater than that of Zap-70.
What is the basis for this striking difference? It is worth mentioning that Syk and SykB, but not Zap-70, were also tyrosine-phosphorylated in COS-1 cells. Nevertheless, it is im- probable that this phosphorylation explained the superior activity of Syk and SykB, as depletion of tyrosine-phosphorylated polypeptides did not alter the relative activity of these molecules in kinase reactions. In other experiments, we also addressed the possibility that a cellular PTK bound to Syk, but not to Zap-70, explained the greater kinase activity found in anti-Syk immunoprecipitates. However, our results provided firm evidence that this activity was intrinsic to Syk, as it was abolished by mutation of the Syk ATP-binding site (data not shown). Finally, the structural basis for this difference in activity of Syk and Zap-70 was determined by constructing chimeras between these two kinases. Our analyses showed that the catalytic sequences of these enzymes, but not their SH2 domains, linker region or carboxyl-terminal tail, conferred their distinct capacities to phosphorylate substrates in vivo and in vitro. While it is likely that Syk has a greater overall PTK activity than Zap-70, it could not be completely ruled out that Syk and Zap-70 actually have distinct substrate specificities. Perhaps Zap-70 is active only toward a limited set of cellular substrates. This possibility is unlikely, however, as Syk was consistently more active than Zap-70 in vitro, under a variety of assay conditions (data not shown). Furthermore, Syk was more efficient than Zap-70 at phosphorylating a variety of PTK substrates in COS-1 cells, including c-Cbl (this report), phospholipase C-␥1, Slp-76, Shc, and HS1. 3 These findings may provide an explanation for the dissimilar impacts of Syk and Zap-70 on cell signaling, which were noted in earlier studies (20, 39) . Antibody-mediated aggregation of a CD16-CD7-Syk chimera, but not of a CD16-CD7-Zap-70 chimera, was sufficient to induce cytolytic functions in a human T-cell line (20) . Similarly, the Syk chimera was more efficient than the Zap-70 chimera at triggering phagocytosis in COS-1 cells (40) . It is plausible that Syk performed better than Zap-70 in these systems, because it has a superior intrinsic PTK activity. Since co-aggregation of the Zap-70 chimera with a Fyn or Lck chimera was needed for activation of T-cell cytotoxic functions (20) , it has been postulated that the function of Zap-70, but not that of Syk, absolutely requires activation of Src family kinases. This concept is in keeping with the observation that phosphorylation of Zap-70 at tyrosine 493 by Src family kinases increased its catalytic activity in vitro (41, 42) and was necessary for Zap-70-mediated functions in vivo (41) . In spite of these differences, Kong et al. (43) observed that Syk and Zap-70 were equally efficient at rescuing antigen receptor-induced signals in Syk-deficient DT-40 chicken B-cells. While this finding may seem to contradict our data, we feel that it indicated that, in the context of the other post-translational modifications triggered by antigen receptor stimulation, Zap-70 can become able to transduce signals as efficiently as Syk. Possibly, the biological activity of Zap-70 is maximized as a consequence of its binding to tyrosine-phosphorylated ITAMs and/or its tyrosine phosphorylation by activated Src family kinases.
Collectively, these observations suggest that the prerequisites for signal transduction by Syk and Zap-70 differ strikingly. While both associate with tyrosine-phosphorylated ITAMs, the higher intrinsic PTK activity of Syk may allow this enzyme to induce intracellular protein tyrosine phosphorylation more readily. Perhaps, Syk-mediated signals can even occur in the absence of activation of Src family members and binding to ITAMs. In contrast, Zap-70-mediated signal transduction may be fully dependent on adequate activation of Srcrelated PTKs and association with tyrosine-phosphorylated ITAMs. Such a distinction would presumably permit a tighter control of Zap-70-mediated signals, which may be crucial to avoid inappropriate T-cell antigen receptor signaling. Even though the biological significance of these differences remains to be firmly established, it is provocative that T-cells can express both Syk and Zap-70, in a developmentally regulated manner (5) . The relative abundance of Syk may dictate the requirement for activated Src family kinases to initiate antigen receptor signaling and be a crucial determinant of T-cell responsiveness.
SykB is an alternative Syk isoform previously identified by cDNA cloning in the human T-cell leukemia line Jurkat (35) and the rat basophilic leukemia line RBL-2H3 (Ref. 36) . While the SykB protein was shown to accumulate in RBL-2H3 cells (36) , its expression was not documented in normal cells in this earlier study. Herein, we report the isolation of a sykB cDNA from mouse thymus. Ribonuclease protection assays showed that ϳ10% of syk RNAs in thymus, spleen, and a variety of hemopoietic cell lines was of the sykB configuration. However, we were unable to undeniably document expression of the SykB protein in these cells. But we found that sykB represented ϳ50% of all syk transcripts and polypeptides present in normal mouse bone marrow cells. Even though the exact cell type(s) containing sykB remain(s) to be determined, our data nonetheless established that SykB is a genuine Syk isoform that may have a unique role in bone marrow cell signaling. Whereas our biochemical analyses indicated that Syk and SykB exhibit comparable intrinsic PTK activity, it is plausible that the deletion in the linker region removes binding sites for other cellular proteins (2), or modifies the conformation of Syk, thereby changing its function and/or regulation. Obviously, future studies are indicated to determine the role of this Syk isoform in hemopoietic cells.
In summary, we have shown that the intrinsic PTK activity of Syk and SykB is significantly greater than that of Zap-70 in transiently transfected COS-1 cells and in hemopoietic cells. Through structure-function analyses, it was also established that this biochemical difference relates to sequence variations in the catalytic domain of the two enzymes. While the full physiological significance of these observations remains to be established, they imply that Syk is more readily efficient at transducing signals in hemopoietic cells. In contrast, the participation of Zap-70 may require additional post-translational modifications, such as binding to tyrosine-phosphorylated ITAMs and/or phosphorylation by Src family kinases. These hypotheses are currently being tested experimentally.
